Hosted on MSN

UniQure stock surges 247% after mid-stage Huntington’s win

A Huntington’s gene therapy by UniQure has made waves after slowing disease progression by 75% in a mid-stage trial. During the Phase I/II study (NCT05243017), patients treated with a high dose of AMT ...

UC Irvine Secures $12M CIRM Grant to Launch Phase 1/2 Stem Cell Trial for Huntington’s

UCI’s $12M CIRM award for hNSC-01 marks a pivotal shift to clinical-stage development. See how this state-funded "bridge" is ...
Business Wire

Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression

Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients ...
Benzinga.com

Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...